Allakos
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Allakos sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Allakos: 15 sponsored US clinical trials, none currently recruiting.
Allakos sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 3 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Eosinophilic Duodenitis, with 2 trials.
Top-decile sponsor footprint
Allakos ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
NCT06577116
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
NCT06072157
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
NCT05528861
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
NCT05155085
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
NCT04856891
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04620811
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
NCT04322708
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04322604
A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers
NCT04324268
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT03664960
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
NCT03496571
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
NCT03379311
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
NCT03436797
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
NCT02734849
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001
NCT02563938
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 3 |
How the Allakos early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 13 completed (87%).
Phase mix: 3 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Eosinophilic Duodenitis (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allakos: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allakos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
- Ascentage Pharma Group · 15 trials · 53% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allakos page
15 registered trials is a research-attention snapshot, not an endorsement of Allakos or any single study.
- None of Allakos's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Eosinophilic Duodenitis is the condition Allakos studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Eosinophilic Duodenitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allakos pipeline card: 15 registered trials from official public datasets.Report a data error.